Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
6605 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2025-01-29 (lifesciencesipreview.com)
Dutch court axes Biogen’s MS patent, clearing way for generics | Europe | Life Sciences Intellectual Property Review
Dutch court axes Biogen’s MS patent, clearing way for generics
Read more
2025-01-28 (juve-patent.com)
Generics companies successfully challenge Biogen's Dutch Tecfidera patent -
The District Court The Hague nullifed the Dutch part of Biogen's Tecfidera patent in a dispute with generics Mylan, Neuraxpharm and Sandoz.
Read more
2024-12-31 (geneonline.com)
A Look at 2024’s Patent Expirations and Generic Competition -
2024's patent expirations, the rise of generics, and their impact on pharmaceutical companies, revenue, and patient access.
Read more
2024-10-28 (ipwatchdog.com)
Understanding the Statute on Patent Term Extension
The Drug Price Competition and Patent Term Restoration Act of 1984, better known as the Hatch-Waxman Act, is responsible for allowing patent owners to extend the patent term due to the need to go through premarket regulatory review.
Read more
2024-10-27 (marketaccesstoday.com)
Biogen’s Patent Win Strengthens TECFIDERA’s Market Position
The European Patent Office (EPO) has delivered a pivotal decision affirming the validity of Biogen's patent EP 2 653 873, securing the company’s foothold in
Read more
2024-08-03 (bloomberglaw.com)
Biogen’s Vumerity Patent Suit Against Zydus Whittled to Validity
Biogen Inc. and Alkermes Plc’s lawsuit over Zydus Lifesciences Ltd.’s proposed generic version of Vumerity is down to the validity of three asserted patents after Zydus agreed its copy of the multiple sclerosis drug infringes.
Read more
2023-10-23 (reut.rs)
Roche settles US patent lawsuit against Biogen over blockbuster arthritis drug
Swiss pharmaceutical company Roche has settled a patent lawsuit against U.S. biotech firm Biogen over its biosimilar version of Roche's blockbuster rheumatoid arthritis drug Actemra, according to a filing on Monday in Massachusetts federal court.
Read more
2023-05-05 (fiercepharma.com)
Biogen chalks up a Tecfidera patent win in Europe after losing US protections
While Biogen’s attempts to resurrect a crucial Tecfidera patent in the U.S. floundered, the company is chalking up a win in Europe. | After its multiple attempts to revive a key patent for multiple sclerosis med Tecfidera in the U.S., Biogen has found success in Europe.
Read more
2023-03-29 (breakingnews.ie)
High Court wrongly found public interest in cheaper drugs overrode patent holder rights | BreakingNews.ie
A judge at the Court of Appeal said the High Court erred in principle in considering that patent holder, Biogen, had a “monopoly to which it was not entitled”
Read more
2021-11-30 (reuters.com)
Biogen loses bid to reverse loss in Mylan MS drug patent dispute
A U.S. appeals court on Tuesday upheld generic drugmaker Mylan's successful challenge to a patent covering Biogen's top-selling multiple-sclerosis treatment, finding the patent didn't sufficiently describe its method for treating the neurological disease.
Read more
2021-05-26 (bloomberglaw.com)
Biogen Loses Appeal in Patent Fight Seeking Royalties on Rebif
Biogen Inc. lost an appeals court ruling in its bid to seek billions of dollars in royalties from the sale of Merck KGaA’s Rebif multiple sclerosis drug.
Read more
2020-01-11 (barrons.com)
Biogen Defends Its Blockbuster Against Mylan’s Patent Challenge
The biotech has already seen its shares buffeted by issues with an experimental Alzheimer’s drug. Now it faces a decision that could hasten generic producers taking a bite out of 40% of its revenues.
Read more